Approved drugs covered in Pureplasma™
Product FeaturesCancer of Any Type Detection: Applicable to instruction of non-invasive individualized medication for solid tumors of many kinds such as gastric cancer, breast cancer, renal cancer, colorectal cancer, pancreatic cancer and GIST, evaluation of therapy effect, and monitoring of diseases.
Safe and Non-Invasive: A substitute for risky and invasive biopsy, based on the peripheral blood ctDNA as specimens;
Comprehensive and Precise: Capable of detecting mutation, fusion, copy number amplification, insertion and deletion in parallel all at once in the aspect of ctDNA with the ultra-high sequencing depth greater than 10000X, and can accurately detect the ultra-low abundance variation lowering to 0.2%, breaking through the limitation of the past monitoring methods;
Comprehensive Detection: Detect the 63 targeted genes for related medicines all at once, covering the targets for all targeting medicines as currently approved by cFDA and FDA, recommended by Guidelines and under clinical trials, providing comprehensive and precise molecular diagnosis basis for subsequent clinical individualized therapy;
Whole Process Monitoring: Actualize a whole process monitoring of targeting therapy efficacy and disease progress.
Applicable PopulationsApplicable to the first- or second-line patients with advanced-stage cancer of any type from whom sufficient tissue specimens cannot be acquired;
Applicable to the patients with cancer of any type recurrence.
Service CycleDetection report is issued within 12 natural days of receipt of specimen.
10ml peripheral blood.